Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15808590 | 0.86 | CHRM4 (0.58) | POLBMMP2MMP13CHRM4RORC | |
| SCHEMBL8916001 | 0.86 | POLB (0.71) | POLBTSHRHTTPKMSMN1; SMN2 | |
| SCHEMBL9081654 | 0.86 | CYP46A1 (0.59) | POLBMMP2MMP13CHRM4RORC | |
| SCHEMBL5790489 | 0.85 | POLB (0.69) | POLBTSHRHTTPKMSMN1; SMN2 | |
| SCHEMBL14626221 | 0.83 | POLB (0.68) | POLBRXFP1TSHRHTTPKM | |
| SCHEMBL14067414 | 0.83 | POLB (0.68) | POLBTSHRHTTPKMSMN1; SMN2 | |
| SCHEMBL14590551 | 0.83 | POLB (0.68) | POLBTSHRHTTPKMSMN1; SMN2 | |
| SCHEMBL24636855 | 0.82 | POLB (0.66) | POLBTSHRHTTPKMSMN1; SMN2 | |
| SCHEMBL4889125 | 0.82 | NOTUM (0.58) | CHRM4RORCKMT2ANOTUM | |
| SCHEMBL1190641 | 0.81 | POLB (0.61) | POLBTSHRHTTPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | POLB 4709/4885MMP2 4630/4885MMP13 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.